PTC Therapeutics Inc (STU:BH3)
€ 68.86 +0.20 (+0.29%) Market Cap: 5.70 Bil Enterprise Value: 4.39 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 56/100

PTC Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 08:15PM GMT
Release Date Price: €51 (-2.86%)
Andrew Francis Galler
Morgan Stanley, Research Division - Equity Analyst

Good afternoon, everyone. I'm Andrew Galler, one of the biotech analysts here at Morgan Stanley, and I'm pleased to be joined today from PTC Therapeutics, Matt Klein, COO; and Kylie O'Keefe, who is the Head of Communications and Global Corporate Strategy.

So I think -- and then before we get started, I want to read out some disclosures. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Questions & Answers

Andrew Francis Galler
Morgan Stanley, Research Division - Equity Analyst

So to start off, I think that PTC is really in a transformational period right now, based on some of the recent milestones you hit and then also some upcoming data catalysts. So maybe if you want to take a few minutes to start to just

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot